Category: SeaPRwire

London, United Kingdom – January 08, 2026 – (SeaPRwire) – Capital Margin Trade has announced a continued focus on strengthening its trading tools, placing practicality ahead of feature volume. The initiative reflects a broader effort to refine how traders interact with the platform on a daily basis, particularly in environments where clarity, timing, and execution discipline tend to outweigh visual appeal or experimental features. The Capital Margin Trade trading platform is built around a straightforward premise. Trading tools should work together smoothly and remain accessible under real market conditions. Market access, charting, and order management are combined within a single interface, reducing the need to switch between sections during active trading. Over time, this type of structure often proves more valuable than frequent interface changes that require constant readjustment. Charting has been one of the more fully formed components of the platform. With multiple chart time frames, layered indicators, and customizable chart layouts, users have an opportunity to evaluate price action without extraneous distractions. The tools continue to remain stable even in times of increased volatility, which is often when stability can become a major issue. While the platform does not aim to replicate institutional-grade software, it offers sufficient analytical depth to support structured technical analysis and routine market monitoring. Execution tools on the Capital Margin Trade broker platform follow a similar logic. Orders can be placed and managed without interrupting the broader workflow, allowing traders to stay focused on market movement rather than interface navigation. Real-time price feeds across supported instruments provide continuous visibility, helping users react as conditions change. Execution speed, as with any platform, remains dependent on market conditions, though overall performance is generally consistent during standard trading hours. Risk management features are integrated directly into the trading process. Users can input a stop-loss and/or take-profit level at the time they enter a trade, or adjust those levels once their trades are active. This provides users with the opportunity to make decisions based upon their own risk assessment without forcing the use of pre-defined automated strategy templates. While some traders may look for deeper automation, others may value the ability to remain closely involved in managing exposure. Beyond execution and charting, the Capital Margin Trade trading platform includes a market overview section that offers context without constant interruptions. Instead of relying on frequent alerts, traders can access summarized information when needed. This quieter approach supports independent analysis and may suit users who prefer to interpret data rather than respond to prompts. Accessibility across devices remains consistent. The Capital Margin Trade broker infrastructure is web-based, allowing traders to access accounts from desktops, laptops, tablets, or smartphones without additional downloads. While mobile trading naturally limits screen space, essential functions such as monitoring positions and placing orders remain available, which can be useful for traders managing positions away from their primary setups. In terms of the way the user interacts with the platform, there are multiple layers of operational complexity. The account settings, margin controls, and view of all open positions are clearly defined and separate from each other, allowing for greater ease of managing exposure to risk without having to navigate through layers of menu options. During active market phases, this clarity can help reduce operational friction. Traders seeking highly customized algorithmic environments may find the setup more manual, though this appears intentional for users who prefer hands-on control. Funding and withdrawal processes follow established industry standards. The platform supports commonly used payment methods and prioritizes reliability over experimentation. While options may seem limited for users seeking alternative payment solutions, transaction procedures remain clear and supported by standard verification processes. Security is treated as a baseline requirement rather than a headline feature. Capital Margin Trade trading platform operations include user verification protocols and encrypted data handling designed to protect account access and transactional information without adding unnecessary complexity to daily use. Overall, the ongoing development of Capital Margin Trade broker services suggests a measured, methodical approach. The emphasis has shifted from seeking rapid expansion and numerous new features every few weeks to maintaining a consistent and reliable trading environment. The steady, long-term nature of this strategy could be attractive to those who have become accustomed to using a platform that they feel comfortable with over time, as opposed to having to adjust to rapidly changing tool behavior and workflow changes at short notice. In addition, for traders who place high value on stability, consistency, and predictability in their trading activities (i.e., those who are able to derive long-term benefits from the familiarity of a consistent trading environment), this long-term approach will likely lead to a more productive long-term trading experience than one based on continuous upgrades. About Capital Margin Trade Capital Margin Trade is an online brokerage firm that provides web-based access to global financial markets, utilizing a web-based trading platform. Capital Margin Trade is focused on providing useful tools to assist traders, along with a stable, functional platform structure that supports traders who take a disciplined, execution-oriented approach to trading versus traders who want to constantly experiment with feature-rich platforms. Media Contact Brand: Capital Margin Trade Contact: Media Relations Team Email: press@capitalmargintrade.com Website: https://capitalmargintrade.com

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

SUMMIT, N.J. – December 05, 2025 – (SeaPRwire) – Leapfrog Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units are expected to commence trading on December 5, 2025 on the Global Market tier of The Nasdaq Stock Market LLC under the symbol LFACU. The Company, which is led by Matthew R. Pollard, Abhay N. Pande and Kevin M. Murphy, is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Each unit sold in the offering consists of one Class A ordinary share (an “ordinary share”) and one half of one redeemable warrant with a strike price of $11.50 per ordinary share exercisable within 5 years of the Company completing an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on the Global Market tier of The Nasdaq Stock Market LLC under the symbols “LFAC” and “LFACW,” respectively. BTIG, LLC is serving as the sole book-running manager of the offering. The underwriters have been granted a 45-day option to purchase up to an additional 1,875,000 units at the initial public offering price to cover over-allotments, if any. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering was made only by means of a prospectus, copies of which, when available, may be obtained by contacting BTIG, LLC, 65 East 55 Street, New York, NY 10022, by emailing ProspectusDelivery@btig.com, or by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Leapfrog Acquisition Corp Leapfrog Acquisition Corp is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or engaging in any other similar business combination with one or more businesses or entities. The Company is led by Chief Executive Officer, Matthew R. Pollard, President and Chief Investment Officer, Abhay N. Pande and Chief Financial Officer, Kevin M. Murphy. The Company will prioritize businesses in the international energy supply chain and critical minerals sectors, including their related infrastructure in its search for attractive merger candidates. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the anticipated use of the proceeds of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the registration statement and prospectus for the Company’s initial public offering. Copies of these documents can be accessed through the SEC’s website at www.sec.gov. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Media Contact Company: Leapfrog Acquisition Corp Contact: Media Team Telephone: +1-201-379-4200 LinkedIn: https://www.linkedin.com/company/leapfrog-acquisition-corporation Email In the US: abhay@leapfrogspac.com Email In Asia: matt@leapfrogspac.com kevin@leapfrogspac.com

Hong Kong - 2025年12月01日 - (SeaPRwire) - 全球领先的现场食物垃圾消化技术公司 ORCA 宣布，与保得工程有限公司（Polytek Engineering Co. Ltd.）建立合作关系，成为其在香港的独家经销商及服务伙伴。此项合作标志着 ORCA 在香港持续扩张的重要一步，并支持其在大湾区及东南亚市场的更广泛布局。 应对香港的食物垃圾挑战 香港在废物管理方面持续面临重大挑战。2023 年，全港每天弃置的都市固体废物（MSW）平均达 10,884 公吨。食物垃圾依然是最大单一废物流，占比 29%，即每日约 3,191 公吨(info.gov.hk)。 政府已取得显著进展——2023 年家庭食物垃圾弃置量下降 12.6%，回收率则由前一年的 32% 上升至 33% (info.gov.hk)。 然而，商业及工业部门每天仍产生近 1,000 公吨的食物垃圾，突显需要具规模性、可持续的解决方案，以配合现有措施，并支持香港的长远减废目标 (epd.gov.hk)。 推动可持续发展的合作关系 ORCA 食物垃圾消化机提供现场处理方案，将食物垃圾转化为环保的排放水，减少运输排放、保护堆填区容量，并协助企业达成可持续发展指标。 保得工程是专业厨房、洗衣房及冷库系统的可靠领导者，拥有数十年设计、供应、安装及售后服务经验。他们在项目设计及构思阶段的角色，使其能够在新建或翻新项目中无缝整合 ORCA 技术，确保从一开始便纳入食物垃圾减量方案。 关于 ORCA ORCA 是现场食物垃圾消化技术的先驱，提供的系统可帮助企业减少对堆填区及运输的依赖、降低温室气体排放，并最终从源头减少食物垃圾。 “这项合作是解决香港迫切食物垃圾问题的重要一步。”ORCA CEO Louis Anagnostakos 表示，“虽然 ORCA 仍将继续作为独立的全球公司运营，但通过将我们的创新技术与保得的工程专长结合，我们能够加速可持续解决方案在商业领域及大湾区的应用。” 关于保得工程有限公司 保得工程有限公司是香港、澳门及中国内地领先的专业厨房、洗衣房及冷库解决方案供应商，业务涵盖设计、供应、安装及长期服务，为客户提供高性能、量身定制的方案。 “保得一直致力于提供高性能、面向未来的厨房及设施方案。”保得工程总经理曾志添（Joseph Tsang）表示，“通过此次独家合作，我们能够在项目最早的设计阶段引入 ORCA， 经过验证的食物垃圾技术，让客户从一开始便将可持续性融入其营运之中。”